PALATIN TECHNOLOGIES INC

PALATIN TECHNOLOGIES INC is a biopharmaceutical company that develops first-in-class medicines by modulating the melanocortin receptor (MCR) system. The company's product candidates are specific therapeutics designed to treat diseases with significant unmet medical needs. Palatin's strategy involves developing products and then collaborating with industry leaders for marketing to maximize commercial potential. The MCR system influences inflammation, immune system response, food intake, metabolism, and sexual function. There are five melanocortin receptors, MC1R through MC5R. Activating or blocking these receptors with specific agonists or antagonists can produce significant pharmacological effects. Palatin's product development primarily focuses on using MC4R agonists for treating obesity. The company is developing MC4R peptides and small molecule agonists for potential use in obesity and metabolic-related disorders, rare MC4R pathway diseases like hypothalamic obesity, and orphan indications. Dependent on available resources, Palatin is also developing MC1R agonist products. These products have the potential to treat inflammatory and autoimmune diseases such as dry eye disease (keratoconjunctivitis sicca), uveitis, diabetic retinopathy, and inflammatory bowel disease. The company believes its MC1R agonist peptides have broad anti-inflammatory effects, utilizing mechanisms of the body's natural melanocortin system to regulate the immune system and resolve inflammation. Additionally, subject to resource availability, Palatin is developing peptides and small molecules that are active at multiple melanocortin receptors, with potential applications in obesity and metabolic-related disorders, rare MC4R pathway diseases like hypothalamic obesity, and orphan indications.